Results 11 to 20 of about 22,314 (175)

Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine. [PDF]

Am J Hematol
American Journal of Hematology, Volume 101, Issue 3, Page 577-580, March 2026.
Konopleva M, DiNardo CD, Sun Y, Jung P, Loghavi S, Potluri J, Dail M, Chyla B, Pollyea DA.   +8 more
europepmc   +2 more sources

Hemi-Orolingual Angioedema in a Patient With VEXAS Syndrome. [PDF]

EJHaem
eJHaem, Volume 7, Issue 1, February 2026.
Suárez EU, Arquero-Portero T, Llamas-Sillero P.   +2 more
europepmc   +2 more sources

Glucose-6-phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine. [PDF]

Cancer
Abstract Background Glucose‐6‐phosphate dehydrogenase (G6PD) deficiency impairs cellular redox balance through reduced NADPH production and is the most common enzymatic disorder‐causing anemia. Venetoclax combined with azacitidine (Ven‐Aza) targets leukemic stem cells by disrupting oxidative phosphorylation and inducing mitochondrial stress. This study
Buchrits S, Rozental A, Korngold N, Algor O, Partouche S, Granot G, Raanani P, Wolach O.   +7 more
europepmc   +2 more sources

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine

Haematologica, 2022
Better understanding of the biology of resistance to DNA methyltransferase (DNMT) inhibitors is required to identify therapies that can improve their efficacy for patients with high-risk myelodysplastic syndrome (MDS).
Theodoros Karantanos, Patric Teodorescu, Marios Arvanitis, Brandy Perkins, Tania Jain, Amy E. DeZern, W. Brian Dalton, Ilias Christodoulou, Bogdan C. Paun, Ravi Varadhan, Christopher Esteb, Trivikram Rajkhowa, Challice Bonifant, Lukasz P. Gondek, Mark J. Levis, Srinivasan Yegnasubramanian, Gabriel Ghiaur, Richard J. Jones   +17 more
doaj   +1 more source

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

Preventive Use of Azacitidine in Patients with Acute Myeloid Leukemia after Haploidentical Allo-BMT

Клиническая онкогематология, 2019
Background. Haploidentical bone marrow transplantation (BMT) can be a reliable alternative if a fully matched donor is not available. The main challenges after BMT are a relapse of major disease, graft-versus-host disease (GVHD), and infections ...
R. Sh. Badaev, D. B. Zammoeva, L. L. Girshova, D. V. Babenetskaya, N. A. Il’ina, Yu. A. Alekseeva, A. Yu. Zaritskey, Dmitrii Vasil’evich Motorin   +7 more
doaj   +1 more source

Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model [PDF]

, 2016
INTRODUCTION. Decreased expression of highly immunogenic cancer-testis antigens (CTA) might help tumor to achieve low immunogenicity, escape immune surveillance and grow unimpeded. Our aim was to evaluate CTA expression in tumor and normal tissues and to
Goliadze, Ekaterine, Guruli, Georgi, Manjili, Masoud H., Petrossian, Albert A., Robinson, Samuel P., Sulek, Jay E., Toor, Amir, Zhou, Shaoqing   +7 more
core   +2 more sources

Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer [PDF]

, 2016
The high affinity nerve growth factor (NGF) NGF receptor, p75NTR, is a member of the tumor necrosis factor (TNF) receptor superfamily that shares a conserved intracellular death domain capable of inducing apoptosis and suppressing growth in prostate ...
Biordi, Leda, Colapietro, Alessandro, Festuccia, Claudio, Ficorella, Corrado, Gravina, Giovanni Luca, Jitariuc, Ana, Mancini, Andrea, Marampon, Francesco, Sanità, Patrizia, Scarsella, Luca   +9 more
core   +2 more sources

A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

Haematologica, 2016
The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to azacitidine in this setting are not well
Sylvain Thépot, Raouf Ben Abdelali, Sylvie Chevret, Aline Renneville, Odile Beyne-Rauzy, Thomas Prébet, Sophie Park, Aspasia Stamatoullas, Agnes Guerci-Bresler, Stéphane Cheze, Gérard Tertian, Bachra Choufi, Laurence Legros, Jean Noel Bastié, Jacques Delaunay, Marie Pierre Chaury, Laurence Sanhes, Eric Wattel, Francois Dreyfus, Norbert Vey, Fatiha Chermat, Claude Preudhomme, Pierre Fenaux, Claude Gardin   +23 more
doaj   +1 more source

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

Haematologica, 2019
Standard treatment for higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low blast acute myeloid leukemia is azacitidine. In single arm studies, adding lenalidomide had been suggested to improve outcomes.
Melita Kenealy, Mark Hertzberg, Warwick Benson, Kerry Taylor, Ilona Cunningham, Will Stevenson, Devendra Hiwase, Richard Eek, Daniela Zantomio, Steve Jong, Meaghan Wall, Piers Blombery, Tracey Gerber, Marlyse Debrincat, Diana Zannino, John F. Seymour   +15 more
doaj   +1 more source